Literature DB >> 17107237

Neurobiology and the natural history of schizophrenia.

Jeffrey A Lieberman1.   

Abstract

Schizophrenia follows a fairly consistent natural history and longitudinal course of illness, and it can be described in the context of four specific clinical stages-the premorbid, prodromal, deterioration, and chronic/residual stages. Many patients treated in their first episode of schizophrenia respond well to treatment and achieve some symptom remission and level of recovery, but recurrent episodes, often brought on by treatment nonadherence or insufficient treatment, lead to more substantial and lasting neurologic deterioration. This presentation describes the clinical stages of schizophrenia and discusses the possibility for prevention of clinical deterioration with early detection and treatment of the illness and sustained maintenance treatment after episodic remission.

Entities:  

Mesh:

Year:  2006        PMID: 17107237

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  20 in total

1.  Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

Authors:  George Bartzokis; Po H Lu; Erika P Raven; Chetan P Amar; Nicole R Detore; Alexander J Couvrette; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2012-07-17       Impact factor: 4.939

2.  Adolescent stress contributes to aberrant dopamine signaling in a heritable rodent model of susceptibility.

Authors:  Stephanie M Perez; Daniel J Lodge
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-07-10       Impact factor: 5.067

Review 3.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 4.  Application of Disease Etiology and Natural History to Prevention in Primary Health Care: A Discourse.

Authors:  Franklin White
Journal:  Med Princ Pract       Date:  2020-05-18       Impact factor: 1.927

5.  Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.

Authors:  George Bartzokis; Po H Lu; Chetan P Amar; Erika P Raven; Nicole R Detore; Lori L Altshuler; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2011-07-20       Impact factor: 4.939

Review 6.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

7.  Rehospitalization risk of former voluntary and involuntary patients with schizophrenia.

Authors:  Carmen Pfiffner; Tilman Steinert; Reinhold Kilian; Thomas Becker; Karel Frasch; Gerhard Eschweiler; Gerhard Längle; Daniela Croissant; Wiltrud Schepp; Prisca Weiser; Susanne Jaeger
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-05-08       Impact factor: 4.328

Review 8.  The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

Review 9.  Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells.

Authors:  Bradley Watmuff; Shaunna S Berkovitch; Joanne H Huang; Jonathan Iaconelli; Steven Toffel; Rakesh Karmacharya
Journal:  Mol Cell Neurosci       Date:  2016-01-14       Impact factor: 4.314

10.  Symptomatic remission in a multiracial urban population of older adults with schizophrenia.

Authors:  Azziza Bankole; Carl I Cohen; Ipsit Vahia; Shilpa Diwan; Nikhil Palekar; Pia Reyes; Mamta Sapra; Paul M Ramirez
Journal:  Am J Geriatr Psychiatry       Date:  2008-12       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.